Follow the WuXi Biologics (Cayman) Inc. share price and the full management transaction log of the company, a publicly traded company based in Hong Kong. Shares are quoted on the HK market, under the supervision of HKEX. Operating in the Health Care sector, WuXi Biologics (Cayman) Inc. has recorded 10 insider filings. Market capitalisation: €159.3bn. The latest transaction was filed on 23 June 2026 (Other). Among the most active insiders: Chen Zhisheng. Every trade is openly available.
Analysts rate WuXi Biologics (Cayman) Inc. Buy (bullish), based on 23 analysts. Average price target: HK$47.20.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
10 of 10 declarations
WuXi Biologics (Cayman) Inc. is a company specializing in biopharmaceutical services, providing development and manufacturing solutions for biological products. It is listed on the Hong Kong Stock Exchange under the symbol XHKG.